These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19622059)

  • 1. Therapeutic interventions ameliorating prion disease.
    Brazier MW; Wall VA; Brazier BW; Masters CL; Collins SJ
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):83-105. PubMed ID: 19622059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered prion protein glycosylation in the aging mouse brain.
    Goh AX; Li C; Sy MS; Wong BS
    J Neurochem; 2007 Feb; 100(3):841-54. PubMed ID: 17144900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.
    Gilch S; Nunziante M; Ertmer A; Schätzl HM
    Vet Microbiol; 2007 Aug; 123(4):377-86. PubMed ID: 17493775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc.
    Aguib Y; Gilch S; Krammer C; Ertmer A; Groschup MH; Schätzl HM
    Mol Cell Neurosci; 2008 May; 38(1):98-109. PubMed ID: 18387818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic effect of anti-PrP monoclonal antibodies in transmissible spongiform encephalopathy mouse models: pharmacokinetic and pharmacodynamic analysis.
    Féraudet-Tarisse C; Andréoletti O; Morel N; Simon S; Lacroux C; Mathey J; Lamourette P; Relaño A; Torres JM; Créminon C; Grassi J
    J Gen Virol; 2010 Jun; 91(Pt 6):1635-45. PubMed ID: 20107012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
    Sasaki K; Minaki H; Iwaki T
    J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases.
    Zuber C; Knackmuss S; Rey C; Reusch U; Röttgen P; Fröhlich T; Arnold GJ; Pace C; Mitteregger G; Kretzschmar HA; Little M; Weiss S
    Mol Immunol; 2008 Jan; 45(1):144-51. PubMed ID: 17576014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP.
    Rambold AS; Miesbauer M; Olschewski D; Seidel R; Riemer C; Smale L; Brumm L; Levy M; Gazit E; Oesterhelt D; Baier M; Becker CF; Engelhard M; Winklhofer KF; Tatzelt J
    J Neurochem; 2008 Oct; 107(1):218-29. PubMed ID: 18691383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling prion diseases: a review of the patent landscape.
    Zattoni M; Legname G
    Expert Opin Ther Pat; 2021 Dec; 31(12):1097-1115. PubMed ID: 34134584
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental transmission of two young and one suspended bovine spongiform encephalopathy (BSE) cases to bovinized transgenic mice.
    Yokoyama T; Masujin K; Yamakawa Y; Sata T; Murayama Y; Shu Y; Okada H; Mohri S; Shinagawa M
    Jpn J Infect Dis; 2007 Sep; 60(5):317-20. PubMed ID: 17881878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
    Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
    J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin.
    Haviv Y; Avrahami D; Ovadia H; Ben-Hur T; Gabizon R; Sharon R
    Arch Neurol; 2008 Jun; 65(6):762-75. PubMed ID: 18541796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methionine sulfoxides on PrPSc: a prion-specific covalent signature.
    Canello T; Engelstein R; Moshel O; Xanthopoulos K; Juanes ME; Langeveld J; Sklaviadis T; Gasset M; Gabizon R
    Biochemistry; 2008 Aug; 47(34):8866-73. PubMed ID: 18680312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New knowledge about Creutzfeldt-Jakob disease can yield therapeutic possibilities].
    Stølsmark T; Tysnes OB
    Tidsskr Nor Laegeforen; 2010 Mar; 130(6):601-4. PubMed ID: 20349004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies.
    Alexandrenne C; Hanoux V; Dkhissi F; Boquet D; Couraud JY; Wijkhuisen A
    J Neuroimmunol; 2009 Apr; 209(1-2):50-6. PubMed ID: 19232746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of prion infectivity and levels of scrapie prion protein by lithium aluminum hydride: implications for RNA in prion diseases.
    Jeong BH; Kim NH; Jin JK; Choi JK; Lee YJ; Kim JI; Choi EK; Carp RI; Kim YS
    J Neuropathol Exp Neurol; 2009 Aug; 68(8):870-9. PubMed ID: 19606066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended period of asymptomatic prion disease after low dose inoculation: assessment of detection methods and implications for infection control.
    Collins SJ; Lewis V; Brazier MW; Hill AF; Lawson VA; Klug GM; Masters CL
    Neurobiol Dis; 2005 Nov; 20(2):336-46. PubMed ID: 16242640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PrPSc level and incubation time in a transgenic mouse model expressing Borna disease virus phosphoprotein after intracerebral prion infection.
    Sakudo A; Onodera T; Ikuta K
    Neurosci Lett; 2008 Jan; 431(1):81-5. PubMed ID: 18155836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity.
    Horiuchi M; Karino A; Furuoka H; Ishiguro N; Kimura K; Shinagawa M
    Virology; 2009 Nov; 394(2):200-7. PubMed ID: 19766283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.